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Abstract
The Lnk adapter protein negatively regulates the signaling of thrombopoietin (TPO), the main 
megakaryocyte (MK) growth factor. Lnk-deficient (−/−) mice have increased TPO signaling and 
increased MK number. Interestingly, several mouse models exist in which increased MK number 
leads to a high bone mass phenotype. Here we report the bone phenotype of these mice. MicroCT 
and static histomorphometric analyses at 20 weeks showed the distal femur of Lnk−/− mice to have 
significantly higher bone volume fraction and trabecular number compared to wild-type (WT) 
mice. Notably, despite a significant increase in the number of osteoclasts (OCs), and decreased 
bone formation rate in Lnk−/− mice compared to WT mice, Lnk−/− mice demonstrated a 2.5-fold 
greater BV/TV suggesting impaired OC function in vivo. Additionally, Lnk−/− mouse femurs 
exhibited non-significant increases in mid-shaft cross-sectional area, yet increased periosteal BFR 
compared to WT femurs was observed. Lnk−/− femurs also had non-significant increases in polar 
moment of inertia and decreased cortical bone area and thickness, resulting in reduced bone 
stiffness, modulus, and strength compared to WT femurs. Of note, Lnk is expressed by OC lineage 
cells and when Lnk−/− OC progenitors are cultured in the presence of TPO, significantly more 
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OCs are observed than in WT cultures. Lnk is also expressed in osteoblast (OB) cells and in vitro 
reduced alkaline phosphatase activity was observed in Lnk−/− cultures. These data suggest that 
both direct effects on OB and OC as well as indirect effects of MKs in regulating OB contributes 
to the observed high bone mass.
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INTRODUCTION
The Lnk adaptor protein (SH2B3) is expressed in hematopoietic tissue and is a known 
negative regulator of cytokine and growth factor signaling in hematopoiesis and 
lymphopoiesis [Huang et al., 1995; Takaki et al., 1997]. Lnk−/− genetically engineered 
mouse models have been instrumental in elucidating the physiologic function of Lnk. Takaki 
et al [Takaki et al., 2000] showed that Lnk−/− mice experience defective B lymphocyte 
production resulting in elevated numbers of B cells in bone marrow (BM), and accumulation 
of B cell progenitors in the spleen. In Lnk−/− mice, Velazquez et al [Velazquez et al., 2002] 
also observed increased extramedullary production of MK and erythrocytes resulting in 
splenomegaly, and increased MK and B cells in the BM and lymph nodes, respectively. 
Peripheral blood analysis revealed significant increases in circulating leukocytes and 
platelets. Partly due to Lnk−/− cell hypersensitivity to cytokines, In vitro analysis 
demonstrated a significant increase in hematopoietic progenitor proliferation and absolute 
number [Velazquez et al., 2002].
Additionally, Lnk is highly expressed in erythroid, MK, and myeloid lineage stem cells. 
These findings suggest Lnk functions as a negative modulator of hematopoietic cell 
proliferation. Furthermore, by exploring Lnk and TPO interactions, Tong and Lodish [Tong 
and Lodish, 2004] found Lnk to negatively regulate TPO induced hematopoietic cell 
proliferation through TPO-c-mpl inhibition. Accordingly, Lnk−/− mice would be predicted to 
exhibit elevated TPO-c-mpl signaling and consequently increased TPO-c-mpl mediated cell 
proliferation. Lnk−/− mice displayed increased numbers of MK and ploidy in the BM and 
spleen. Consistent with these findings, Lnk−/− MK exhibited enhanced in vitro proliferative 
response through STAT3, STAT5, Akt and MAPK signaling pathways. Hence, Lnk has been 
well established as a key mediator of hematopoiesis and role player in MK proliferation and 
development.
MK are hematopoietic thrombocyte progenitor cells that originate in the BM. Burgeoning 
research demonstrates MK to play a critical role in skeletal homeostasis by surrounding and 
interconnecting functionally with bone cells [Kacena et al., 2006a; Kacena et al., 2006b]. In 
vitro studies confirm MK express and/or secrete several bone-related proteins that stimulate 
OB proliferation and bone formation [Beeton et al., 2006; Bord et al., 2005; Breton-Gorius 
et al., 1992; Chagraoui et al., 2003; Cheng et al., 2013; Cheng et al., 2015; Chenu and 
Delmas, 1992; Ciovacco et al., 2010; Ciovacco et al., 2009; Eleniste et al., 2016; Frank et 
al., 1993; Kacena et al., 2012; Kacena et al., 2006b; Kelm et al., 1992; Pearse et al., 2001; 
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Sipe et al., 2004; Thiede et al., 1994]. Furthermore, at least 4 mouse models have been 
described in which significantly elevated MK numbers lead to increases in bone mass. TPO 
overexpression in mice leads to approximately a 4-fold increase in MK number and an 
osteosclerotic bone phenotype [Villeval et al., 1997; Yan et al., 1996]. We previously 
demonstrated that mice deficient in GATA-1 or NF-E2, transcription factors required for 
mature MK development, had elevated numbers of MK and developed high bone mass 
[Kacena et al., 2005; Kacena et al., 2004]. More recently, a similar phenotype exhibiting 
increased MK numbers accompanied by high bone mass phenotype was observed in a 
platelet-type von Willebrand disease mouse model with a gain-of-function (GOF) mutation 
[Suva et al., 2008]. In the current study, we examine whether Lnk−/− deficiency in mice 
regulates bone mass phenotype.
METHODS
MICE
For these studies 5-month-old female and male WT C57BL/6 and Lnk−/− mice were utilized. 
Lnk−/− mice are on a C57BL/6 background and were kindly provided by Dr. T. Pawson 
(Samuel Lunenfeld Research Institute, Toronto, Canada), and C57BL/6 mice were obtained 
from Jackson Laboratories (Maine). The generation and breeding of Lnk−/− mice was 
previously described [Tong and Lodish, 2004; Velazquez et al., 2002]. The Institutional 
Animal Care and Use Committee (IACUC) of the Indiana University School of Medicine 
approved all procedures. NIH Guidelines and the Guide for the Care and Use of Laboratory 
Animals were followed.
HISTOMORPHOMETRY
Actively forming bone surfaces of WT and Lnk−/− mice were labeled by intraperitoneal (IP) 
injections of the fluorochrome calcein (30mg/kg; Sigma) at 13 and 3 days prior to sacrifice. 
At sacrifice, the left femur was removed and stored in 10% neutral buffered formalin for 24-
hours, followed by storage in 70% alcohol. The right femur was removed, wrapped in saline 
soaked gauze and stored at −80C for biomechanical analysis. Femoral trabecular (distal 
region) and cortical (mid-shaft region) bone was analyzed by static and dynamic 
histomorphometry as previously described [Feher et al., 2010; Warden et al., 2008]. Mid-
sagittal sections of 8 μm were cut by a Reichert-Jung 2050 microtome (Magee Scientific, 
Inc) and stained with McNeal’s tetrachrome for static histomorphometry. Mid-sagittal 
sections of 8 μm were cut and left unstained for dynamic histomorphometry and wall 
thickness analysis. A semiautomatic analysis system (Bioquant OSTEO 7.20.10, Bioquant 
Image Analysis Co.) attached to a microscope with an ultraviolet light source (Nikon 
Optiphot 2 microscope, Nikon) was used to make histological measurements on one stained 
(static) and unstained (dynamic) section for each animal.
Micro-Computed Tomogograhy
As previously described, micro-computed tomography (microCT; Skyscan 1172; Skyscan, 
Kontich, Belgium) was used to quantify trabecular and cortical bone parameters of the distal 
and mid-shaft femur [Feher et al., 2010; Warden et al., 2008; Weatherholt et al., 2013]. 
Femurs were scanned at with at an energy level of 60 Kv, isotropic voxel size of 9μm, and 
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0.5mm filter, while a 1mm thick region of trabecular bone was analyzed at 0.5 mm distal to 
the growth plate. Binarized images were used to calculate the following three-dimensional 
bone volume parameters: trabecular bone volume (BV/TV, %), trabecular number (Tb.N, 1/
mm), trabecular thickness (Tb.Th, mm), and trabecular separation (Tb.Sp, mm) using 
NRecon reconstruction software (Skyscan).
BIOMECHANICS
A materials testing device (MTS Systems Corporation; Eden Prairie, MN) was used to 
determine relative bone strength by three-point bending as previously described [Feher et al., 
2010; Warden et al., 2008; Weatherholt et al., 2013]. The right femurs were thawed to room 
temperature in a saline bath for 2h prior to testing. Femurs were placed in a saline bath at 
37°C and stabilized with a static preload of 1 N in the anterior-posterior direction, and 
loaded to failure with a crosshead speed of 10 mm/min. Calculations of force (N), stiffness 
(N/mm), polar moment of inertia, ultimate stress (MPa), modulus (MPa), and toughness 
(MJ/m3) were computed from force versus displacement data collected at 100 Hz.
PREPARATION OF NEONATAL CALVARIAL CELLS (OB)
Neonatal murine calvarial OB were prepared from WT C57BL/6 and Lnk−/− mice as 
previously described [Chitteti et al., 2010]. Our technique was modified from the basic 
method described by Wong and Cohn [Wong and Cohn, 1975]. Dissected neonatal mice 
calvarias were treated with EDTA in PBS for 30 min and subjected to sequential collagenase 
digestions (200 U/ml). The starting OB population consisting of ~90% OB and OB 
precursors were collected from fractions 3–5 where digestions were incubated at 37°C for 
20–35, 35–50, and 50–65 min, respectfully [Horowitz et al., 1994; Jilka and Cohn, 1981; 
Simmons et al., 1982]. Seeded at optimal pre-tested conditions (2x104 cells/ml), OB were 
maintained in αMEM supplemented with 10% fetal bovine serum (FBS), ascorbic acid (50 
μg/ml added on day 0, and at all feedings), and β-glycerophosphate (5mM added starting on 
day 7, and all subsequent feedings). Cells were replenished twice per week, and some 
cultures were administered TPO (100 ng/ml) to stimulate MK as described [Meijome et al., 
2015].
PREPARATION OF FETAL LIVER DERIVED MEGAKARYOCYTES
Murine MK were prepared as previously described [Kacena et al., 2006b; Kacena et al., 
2004]. Fetal livers obtained from pregnant C57BL/6 mice at E13–15 were prepared into 
single cell suspensions, washed, and cultured in 100 ml dishes with Dulbecco modified 
eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% murine 
TPO [Villeval et al., 1997]. A 90–95% pure MK population was isolated from lymphocytes 
and other cell types using a one-step albumin gradient after ~5 days [Drachman et al., 1997].
CELL CYCLE ANALYSIS
A FACS caliber flow cytometer (BDIS) was used to determine the percentage of cells in 
G0/G1 and S/G2 + M phases of WT C57BL/6 and Lnk−/− calvarial OB on days 1, 3, 5, and 
7 of culture. Cells were prepared as previously described [Srour et al., 1992]. OB were 
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labeled with a staining cocktail mixture of propidium iodide (0.1 mg/ml), Nonidet P40 
(0.6%) in PBS (1:1; v/v), and RNase (2 mg/ml) prior to mixing and 30 min ice incubation.
APOPTOSIS ANALYSIS
A FACs caliber flow cytometer (BDIS) was used to assess apoptosis of WT C57BL/6 and 
Lnk−/− calvarial OB on days 1, 3, 5, and 7 of culture. Cells were washed once in DMEM, 
incubated on ice for 15 min, and stained with the highly fluorescent allophycocyanin (APC) 
annexin V conjugate (eBioscience, San Diego, CA). Cells were washed and re-suspended 
with DMEM, stained with 10 μl of 10 ng/ml propidium iodide, and incubated at RT before 
analysis.
ALKALINE PHOSPHATASE ACTIVITY
The colorimetric conversion hydrolyzing p-nitrophenol phosphate to p-nitrophenol (Sigma, 
St. Louis, MO) was used to determine alkaline phosphatase activity. Samples were 
normalized to total protein BCA (Pierce, Waltham, MA) [Hughes and Aubin, 1998]. 
Calvarial OB at 2 days old were cultured for 14 days, washed with PBS (2X) and lysed with 
0.1% (v/v) Triton X-100 containing protease inhibitors (Pierce, Waltham, MA). Lysates 
were then subjected to two freeze-thaw cycles, centrifuged, and incubated with 3 mg/ml p-
nitrophenol phosphate in an alkaline buffer, pH 8.0, (Sigma, St. Louis, MO) for 30 min at 
37°C. NaOH (20 mM) conversion of p-nitrophenol to p-nitrophenolate quenched the 
enzyme-catalyzed reaction. Plates were read at 395 nM (GENios Plus, Tecan) and alkaline 
phosphate enzyme activity was determined by comparison with known p-nitrophenol 
standards (Sigma, St. Louis, MO).
QUANTITIVE ANALYSIS OF CALCIUM DEPOSITION
Neonatal calvarial OB were analyzed for calcium deposition after 2 weeks of culture by 
eluting Alizarin Red S (Sigma Chemical Co., St. Louis, MO) from OB monolayers as 
previously described [Stanford et al., 1995]. Cell monolayers were washed with PBS (2X), 
fixed in ice-cold ethanol (70%; v/v) for 1 h, and washed with water (2X). Alizarin Red S 
(40mM; pH 4.2) staining was achieved after 10 min shaking at RT, then unbound dye was 
removed by washing with water (5X) and with PBS (1X for 15min, RT, shaking). To elute 
bound Alizarin Red for quantification, OB monolayers were incubated for 15 min at RT 
under shaking with cetypyridinium chloride (1%; v/v) in sodium-phosphate (10mM; pH 
7.0). Absorbance from aliquots was measured at 562 nm (GENios Plus, Texan), and Alizarin 
Red concentrations were calculated from measured standards (Ca/mol of dye in solution).
PREPARATION OF BONE MARROW CELLS
WT C57BL/6 and Lnk−/− mice tibiae and femurs were dissected at 6–10 weeks of age. 
Following removal of the epiphyses, the BM was flushed with a 27-gauge needle and 
syringe using 2–3 mls of ice cold α-MEM supplemented with 10% FCS (v/v).
BM cells were suspended into single cells and washed twice prior to use.
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PREPARATION OF BONE MARROW MACROPHAGES
BM cells were prepared as above. BM cells at 5x107 cells/ml were cultured in 100 mm 
tissue culture dishes containing α-MEM supplemented with 10% FCS and 20 ng/ml of M-
CSF (Peprotech, Rocky Hill, NJ). After 3 days in culture, adherent cells were dislodged with 
trypsin, and adjusted to 1 x 105 cells/ml concentration for OC generation as described below.
IN VITRO OSTEOCLAST-LIKE CELL FORMATION MODELS
BMM (1x105) were cultured in α-MEM supplemented with 10% FCS, 30 ng/ml of M-CSF 
(R&D Systems, Minneapolis, MN), and 50 ng/ml RANKL (R&D Systems, Minneaspolis, 
MN). Media was changed every third day for 6–8 days pending OC formation, fixed with 
2.5% glutaraldehyde in PBS for 30 minutes at RT, and TRAP stained. Only TRAP+ 
multinucleated cells (>3 nuclei) were quantified. TPO (100 ng/ml; Peprotech, Rocky Hill, 
NJ) was added to some cultures.
CELL STIMULATION AND LYSIS
BMM, RAW 264.7, MK, and Ba/F3 cells from C57BL/6 and Lnk−/− or cell lines grown to 
~75% confluency were treated with reduced serum media (0.5%) for 16–18 hours. Cells 
were treated with human recombinant TPO (100 ng/ml) for 0, 1, 3, 5, 10, and 30 min in the 
presence of 100 μM sodium orthovanadate. Immediately after each incubation period, cells 
were rinsed twice with inhibitor-laced ice-cold (Halt Protease Inhibitor Cocktail and Halt 
Phosphatase Cocktail, Pierce). After aspirating the PBS and inhibitor wash, cells were 
placed (adherent cells were scraped) in lysis buffer containing: Tris (20 mM; pH7.2), NaCl 
(150 mM), Triton X-100 (1.0%), sodium deoxycholate (1.0%), SDS (0.1%), EDTA (5.0 
mM), and protease and phosphatase inhibitors (Pierce). Lysates were centrifuged at 12,000 x 
g for 15 min at 4°C, and supernatants were collected. Protein concentration was determined 
using a BCA protein assay kit with BSA as the standard. Each sample was normalized for 
protein concentration prior to immunoprecipitation (IP) analyses or Western blotting.
IMMUNOPRECIPITATION ASSAYS AND WESTERN BLOTTING
For IP analyses, OB were rinsed with ice-cold PBS and lysed in modified RIPA (mRIPA) 
buffer containing Tris-HCl (50 mM; pH 7.4), NaCl (150mM), EDTA (5mM), NP40 (1%), 
sodium deoxycholate (1%), SDS (0.1%), NaF (50mM), aprotinin (1%), and Na3VO4 (0.1 
mM). To obtain soluble cell extracts, cells were further lysed by sonication and centrifuged 
at 13,000 rpm for 5 min at 4°C. Approximately 150 μg of lysates were incubated with 3 μg 
of Lnk antibody from Millipore (Billerica, MA) for 2h at 4°C. After incubation, 20 μl of 
Protein G-agarose beads were added to individual tubes for 1h at 4°C. Beads were washed 
four times with mRIPA before washing once with 40 μl of 2X Laemmli’s sample buffer with 
β-mercaptoethanol, and immunoblotted with an anti-rabbit secondary antibody (Promega, 
Madison, WI).
For IP, Protein A-Sepharose was used to preclear cell lysates (200–500 μg) for 1 hour at 4°C 
before removing and incubating cell supernatants with appropriate antibody (e.g. Lnk) for 2–
16 hours at 4°C (Millipore). After incubating for 30–60 minutes, antigen-antibody 
complexes were recovered with rabbit anti-mouse immunoglobulin and protein A-Sepharose 
or protein A-Sepharose alone. Immune complexes were washed 3–5 times with lysis buffer, 
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and proteins were eluted into SDS-PAGE sample buffer (3% SDS, 60mM Tris, pH 6.9, 2 
mM EDTA, 4% glycerol) by heating samples to 100°C for 5 minutes.
Under reducing conditions, immunoprecipitated samples (total cell lysates, 25–30 μg) were 
analyzed by 10% SDS-PAGE. Proteins were transferred to nitrocellulose via electrophoresis 
and Western blotted as described in the ECL system (Amersham, Pittsburgh, PA). For blot 
reprobing, nitrocellulose membranes were stripped of antibodies in a solution containing 
glycine (0.1 M; pH2.8) at 55°C for 30 minutes.
STATISTICS
All data are presented as the Mean ± 1 SD unless otherwise stated. Experiments were 
performed at least three times in duplicate or triplicate. In vivo study sample sizes are 
presented in the corresponding figure legends, and Student’s t-tests were performed when 
only two groups were compared. As male and female mouse bones exhibit virtually identical 
properties, for ease of reporting, and to increase sample size, data from male and female 
mice were combined for all in vivo data analysis. One-way Analysis of Variance (ANOVA) 
with least significant difference (LSD) was used to make multiple group comparisons.
RESULTS
Anthropometrics, Cortical Bone, Biomechanical and Biomaterial Properties
Body weight of Lnk−/− and WT C57BL/6 mice were similar for 20 week-old mice. 
Similarly, no significant differences were detected between Lnk−/− and WT mice for femoral 
length, mid-shaft width (medial to lateral), or mid-shaft height (ventral to dorsal) (Table 1) 
with respect to femoral geometry. Consistent with the mid-shaft width and height the cross-
sectional area (CSA, Table 1), polar moment of inertia (Table 2) revealed a non-significant 
increase with Lnk deficiency.
However, the bone area (BA) was found to be significantly higher in WT femurs compared 
to Lnk−/− femurs (10% increase, p<0.01). Lnk−/− mice displayed a significant 78% increase 
in periosteal bone formation rate (p<0.01), but no difference in endocortical bone formation 
rate was observed.
With regard to biomechanical properties, Lnk−/− femurs were significantly less strong (12% 
reduction, p<0.001), less stiff (19% reduction, p<0.001), and failed at lower loads (15% 
reduction, p<0.001) than their WT mice. The modulus was also significantly lower (27% 
reduction, p<0.001) in Lnk−/− femurs compared to that observed in controls.
TRABECULAR BONE PHENOTYPE OF 20-WEEK-OLD LNK−/− Mice
With respect to trabecular bone analyses, static histomorphometry and μCT data were 
obtained and are reported in Table 3 and Figure 1. Bone volume/tissue volume (BV/TV) was 
significantly elevated 2.5-fold in Lnk−/− mice compared to WT controls (p=0.005) by static 
histomorphometry, and 2.1-fold (p<0.001) by μCT. Structural indices of bone analysis 
revealed a significant increase in trabecular number (Tb.N, 2.3-fold increase, p<0.001) with 
concomitant decrease in trabecular separation (Tb.Sp, 1.4-fold decrease, p<0.001) in Lnk−/− 
femurs compared to WT controls. No differences were detected in trabecular thickness 
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(Tb.Th). There was a significant, 11% reduction (p<0.001) detected in the structural model 
index (SMI) in Lnk−/− femurs compared to WT femurs.
Further examination between WT and Lnk−/− femurs with respect to static bone 
histomorphometry parameters illustrated at 5 months of age there were no significant 
differences in the number of OB/tissue area (N.Ob/TAR) between Lnk−/− and WT femurs. 
However, there was a significant 1.7-fold increase in the number of OCs/tissue area (N.Oc/
TAR, p=0.001) in Lnk−/− femurs compared to that observed in WT mice. Dynamic bone 
histomorphometric analyses revealed a significant 1.3-fold decrease (p<0.05) in bone 
formation rate/tissue volume (BRF/TV) and a 1.2-fold decrease (p<0.05) in mineral 
apposition rate (MAR).
LNK IS EXPRESSED IN OSTEOBLAST LINEAGE CELLS
Since global deficiency of Lnk resulted in a high bone mass phenotype by 5 months of age 
with changes in both bone formation and resorption parameters in vivo, we investigated 
possible cellular mechanisms leading to this phenotype. First, we examined cells of the OB 
lineage. As shown in Figure 2A, expression of Lnk was observed in MKs (positive control) 
and in WT OB, but not in Lnk−/− (negative control).
LNK EXPRESSION DOES NOT IMPACT OSTEOBLAST PROLIFERATION
To begin to understand the role of Lnk expression in OB function, we next sought to 
determine whether Lnk expression affected OB number or cell cycle regulation. To 
accomplish this, equal numbers of WT and Lnk−/− OB were seeded and assessed on days 1, 
3, 5, and 7 for the total number of viable OB (trypan blue exclusion) produced in culture as 
well as their cell cycle status (Fig 2B, C). No differences in OB number or cell cycle were 
observed. Of interest, we also cultured OB in the presence or absence of TPO (Peprotech, 
Rocky Hill, NJ). Supplementation with 100 ng/ml of TPO did not have an effect on total 
number of OB progeny or their cell cycle status. Finally, we also assessed apoptosis by 
examining the expression of Annexin V. In all cases, less than 2% of the OB were Annexin 
V positive, suggesting that apoptosis was not altered based on genotype or TPO 
supplementation.
LNK EXPRESSION DOES NOT AFFECT OB DIFFERENTIATION IN VITRO
To understand the effects of Lnk expression and signaling on OB differentiation, we 
examined the following four groups of cells: WT OB, WT OB + TPO, Lnk−/− OB, Lnk−/− 
OB + TPO. Cells were cultured under osteogenic conditions as detailed above. As shown in 
Figure 3A and B, we assessed alkaline phosphatase activity and measured bound calcium as 
a functional measure of mineralization after 10 or 14 days, respectively. No significant 
differences were detected between WT and Lnk−/− OB for mineralization (Figure 3A), but 
Lnk−/− OB alkaline phosphatase activity was markedly reduced (Figure 3B). Furthermore, 
the addition of 100 ng/ml of TPO did not have a notable effect on WT or Lnk−/− OB alkaline 
phosphatase activity or mineralization.
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THE EFFECTS OF LNK EXPRESSION ON OC
Next, we examined whether cells of the OC lineage express Lnk. In Figure 4A, using 
Western blot analysis we show Lnk is expressed in BMM (OC progenitors), RAW 264.7 
cells (OC progenitor cell line), and MK (positive control). We then examined the ability of 
WT and Lnk BMM to differentiate into OC. Figure 4B shows OC number when C57BL/6 
and Lnk−/− BMM were cultured with M-CSF (30 ng/ml) and RANKL (50 ng/ml) in the 
absence or presence of 100 ng/ml TPO. Only TRAP+ multinucleated cells (>3 nuclei) were 
counted. TPO significantly enhanced OC number in cells generated from C57BL/6 and 
Lnk−/− mice. Significantly (p<0.05) more OC were generated from Lnk−/− mice compared to 
WT mice. OC cell counts were normalized to 100 in the WT controls (0 ng/ml TPO) for 
ease of comparison.
DISCUSSION
Several mouse models with megakaryocytosis have been associated with the development of 
a high bone mass phenotype resulting from MK-mediated increase in OB proliferation and 
bone formation. We previously showed that in vitro MK enhance OB proliferation 3–6 fold 
by a direct cell-to-cell contact mechanism [Kacena et al., 2004]. Prior in vivo studies support 
our in vitro evidence that MK induce an OB proliferative net increase in bone formation, as 
mice overexpressing the MK growth factor TPO, experience a marked 4-fold increase in 
absolute MK number versus WT controls and develop a myelofibrotic syndrome with 
osteosclerosis by nine months of age [Frey et al., 1998; Villeval et al., 1997; Yan et al., 1995; 
Yan et al., 1996]. Considering this trend and the inhibitory regulation of TPO/c-mpl 
signaling by Lnk regulation of TPO, the main MK growth factor, we hypothesized that 
Lnk−/− mice would also have a high bone mass phenotype. Here we examine a similar 
mouse model involving dysregulation of TPO signaling. However, instead of up-regulating 
TPO expression, we instead removed Lnk, a negative regulator of TPO signaling, which 
allows for increased communication between TPO and its receptor, c-mpl.
In this study we examined the bone mass phenotype of Lnk−/− mice. Like the TPO 
overexpression model, Lnk−/− mice have an expected increase in MK number, and taken 
collectively the above data predict that the increased TPO-c-mpl signaling would also lead to 
a similar high bone mass phenotype (likely owing to increased MK stimulating increases on 
OB and bone formation). As predicted, Lnk−/− mice developed high bone mass compared to 
WT controls. Specifically, at 5 months of age Lnk−/− femurs had significant elevated 
trabecular BV/TV and Tb.N with a concomitant decrease in Tb.Sp. However, 
histomorphometric analysis did not show the predicted increase in N.Ob/T.Ar or BFR/TV. 
Indeed, no differences in N.Ob/T.Ar were observed and BFR/TV was actually significantly 
reduced in Lnk−/− femurs. We posit these seemingly contradictory findings are a result of the 
timing of these studies. We suggest that MK stimulated OB proliferation and bone 
deposition at an earlier time, which was not captured here, but resulted in the increase in 
BV/TV (a high turnover state like previously reported in other mouse strains with 
megakaryocytosis and high bone mass) [Frey et al., 1998; Kacena et al., 2004; Villeval et al., 
1997; Yan et al., 1995; Yan et al., 1996]. The numbers of active OB then likely normalized 
with time. Of note, when we examined OB lineage cells generated from Lnk−/− and WT 
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mice, we found that while OB express Lnk, no differences in proliferation or mineralization 
were observed, although reduced alkaline phosphatase activity was observed in OB 
generated from Lnk−/− mice. That said, stimulation with TPO did not impact any of these in 
vitro findings. This suggests that Lnk itself may impact OB function (alkaline phosphatase 
activity) but at least based on our assays reported here, these parameters were not altered by 
stimulation of cells with TPO (Figs 2 and 3).
In addition to examining the impact of Lnk expression on OB lineage cells, we also 
examined the impact of Lnk expression on OC lineage cells. We found that OC progenitors 
express Lnk and that generation of mature OC from Lnk−/− mice resulted in a significant 
upregulation in mature OC number in vitro (Fig 4) and in vivo as was documented by the 
significant upregulation in N.Oc/T.Ar observed in Lnk−/− mice (Table 3). Further, we 
demonstrated that stimulation of OC progenitors with TPO increased mature OC number in 
cultures generated from both WT and Lnk−/− mice (the former confirms our previous 
findings, [Bethel et al., 2015]). Lnk−/− OC progenitors are more responsive to TPO 
presumably because removal of Lnk improves TPO signaling.
That said, it is possible that although OC number increases, bone resorbing activity in 
Lnk−/− OC may be altered.
It is important to realize that our group and others have previously demonstrated that MK 
can inhibit OC formation in vitro [Beeton et al., 2006; Kacena et al., 2006b; Wakikawa et 
al., 1997]. Indirectly, MK have been implicated to inhibit osteoclastogenesis by increasing 
OB expression of osteoprotegerin (OPG), a known inhibitor of OC formation [Bord et al., 
2005]. In addition, MK have been implicated as secreting a, yet to be identified, factor(s) 
which can significantly inhibit OC development in vitro [Kacena et al., 2006a]. Interestingly, 
these studies and recently published studies from our laboratory demonstrate TPO and MK 
opposing roles in the regulation of OC formation [Bethel et al., 2015].
Although the interaction between BM cells such as MK and OB lineage cells occurs in the 
BM cavity where trabecular bone parameters were measured, we would be remiss if we did 
not examine the cortical bone phenotype observed in these mice. To this end, cortical 
histomorphometric and μCT parameters as well as biomechanical properties were assessed 
in Lnk−/− and WT mice. WT femurs proved stronger, stiffer, and had a higher ultimate 
failure than did Lnk−/− femurs. The observed increases in WT biomechanical properties are 
likely owing to the increase in cortical BA observed in WT mice with the same overall outer 
geometry (e.g. no significant differences in gross femur width or height and no differences in 
CSA).
Further, we would be remiss not to mention that there are other cell lineages directly affected 
by Lnk deficiency with noted effects on skeletal homeostasis. Indeed, Takaki et al showed 
Lnk−/− mice to have defective B lymphocyte production, with increased numbers of B cells 
in the BM cavity and spleen [Takaki et al., 2000]. Importantly, there exist at least 2 mouse 
models with defects in B-lymphocyte development, and conflicting effects on skeletal 
homeostasis. In fact, absence of Pax5, the gene coding for B-lymphocyte transcription 
factor, leads to arrested B-cell development, an increase in OC progenitor number, and 
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develop early onset osteopenia [Horowitz et al., 2004]. Conversely, mice deficient in EBF-1, 
another B-cell transcription factor, have increased OB and increased bone formation 
parameters [Horowitz and Lorenzo, 2007]. Thus B-lymphocytes are another cell lineage 
directly affected in Lnk−/− mice which may contribute to changes in bone homeostasis for 
this model.
The significance of these findings lends to recognition of the difficulties of interpreting 
results of cell lineages studied in vitro, isolated from their natural tissue environment. Figure 
5 is a schematic representation illustrating the complexity of the cell-cell interactions as 
described in our present findings and previously published data [Meijome et al., 2015]. The 
BM cavity contains MK, OB, OC, and TPO. Bone phenotype is a result of a complex 
interplay between all elements. In prior mouse models, the proliferative effect of MK on OB 
was the presumed dominant interaction. In Lnk−/− mice, however, it appears that this direct 
and indirect effect of TPO on OC formation is also of critical importance.
By continuing to dissect the interaction between hematopoietic and bone cell lineages, the 
mechanisms regulating skeletal homeostasis are clarified. A better understanding of skeletal 
pathology and diseases of dysregulated bone turnover will pave the way for future 
therapeutic intervention.
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
Olivos et al. Page 19
J Cell Biochem. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Olivos et al. Page 20
Ta
bl
e 
1
A
nt
hr
op
om
et
ric
s a
nd
 c
or
tic
al
 b
on
e 
hi
sto
m
or
ph
om
et
ry
 p
ro
pe
rti
es
, 2
0 
w
ee
k-
ol
d 
Ln
k−
/−
 
an
d 
W
T 
m
ic
e
A
nt
hr
o
po
m
et
ri
cs
C
or
tic
al
 B
on
e H
ist
om
or
ph
om
et
ry
M
ic
e
n
Le
ng
th
 (m
m)
W
id
th
 (m
m)
H
ei
gh
t (
mm
)
n
C
SA
 (μ
m2
)
BA
 (μ
m2
)
Pe
ri
os
te
al
 B
FR
 (μ
m2
/μ
m
3 /d
ay
)
En
do
co
rt
ic
al
 B
FR
 (μ
m2
/μ
m
3 /d
ay
)
C5
7B
L/
6 
(W
T)
37
15
.3
 ±
 0
.1
1.
74
 ±
 0
.0
3
1.
29
 ±
 0
.0
2
19
1.
72
 ±
 0
.0
4
0.
86
 ±
 0
.0
5
17
 ±
 4
53
 ±
 2
Ln
k−
/−
18
15
.3
 ±
 0
.1
1.
81
 ±
 0
.0
4
1.
28
 ±
 0
.0
2
17
1.
88
 ±
 0
.0
7
0.
77
 ±
 0
.0
2*
32
 ±
 2
*
48
 ±
 2
Le
ng
th
, d
ist
al
 to
 p
ro
xi
m
al
 fe
m
ur
 le
ng
th
; W
id
th
, m
ed
ia
l t
o 
la
te
ra
l f
em
ur
 w
id
th
; H
ei
gh
t, 
ve
n
tr
al
 to
 d
or
sa
l f
em
ur
 h
ei
gh
t; 
CS
A
, c
ro
ss
-s
ec
tio
na
l a
re
a;
 B
A
, b
on
e 
ar
ea
; P
er
io
ste
al
 B
FR
, p
er
io
ste
al
 b
on
e 
fo
rm
at
io
n 
ra
te
; E
nd
oc
or
tic
al
 B
FR
, e
nd
oc
or
tic
al
 b
on
e 
fo
rm
at
io
n 
ra
te
.
R
es
ul
ts 
ar
e 
pr
es
en
te
d 
as
 m
ea
n 
± 
SE
M
;
*
In
di
ca
te
s s
ig
ni
fic
an
t d
iff
er
en
ce
 c
om
pa
re
d 
w
ith
 W
T 
(p<
0.0
5)
J Cell Biochem. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Olivos et al. Page 21
Ta
bl
e 
2
B
io
m
ec
ha
ni
ca
l b
io
m
at
er
ia
l p
ro
pe
rti
es
, 2
0 
w
ee
k-
ol
d 
Ln
k−
/−
 
an
d 
W
T 
m
ic
e
Bi
om
ec
ha
ni
ca
l a
nd
 B
io
m
at
er
ia
l p
ro
pe
rt
ie
s
M
ic
e
n
Po
la
r 
M
O
I (
mm
4 )
M
od
ul
us
 (M
Pa
)
Lo
ad
 a
t P
ea
k 
(N
)
St
iff
ne
ss
 (N
/m
m)
U
lti
m
at
e F
a
ilu
re
 (M
Pa
)
C5
7B
L/
6 
(W
T)
37
0.
36
 ±
 0
.0
1
42
79
7 
± 
16
97
23
.0
 ±
 0
.4
12
3 
± 
4
24
9 
± 
6
Ln
k−
/−
18
0.
40
 ±
 0
.0
2
31
29
1 
± 
29
01
*
20
.3
 ±
 0
.6
*
10
0 
± 
5*
21
1 
± 
9*
Po
la
r M
O
I, 
po
la
r m
om
en
t o
f i
ne
rti
a.
R
es
ul
ts 
ar
e 
pr
es
en
te
d 
as
 m
ea
n 
± 
SE
M
;
*
In
di
ca
te
s s
ig
ni
fic
an
t d
iff
er
en
ce
 c
om
pa
re
d 
w
ith
 W
T 
(p<
0.0
5)
J Cell Biochem. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Olivos et al. Page 22
Ta
bl
e 
3
Tr
ab
ec
ul
ar
 b
on
e:
 μ
CT
 a
nd
 st
at
ic
 h
ist
om
or
ph
om
et
ric
 a
na
ly
sis
 o
f t
he
 d
ist
al
 fe
m
ur
 o
f 2
0 
w
ee
k-
ol
d 
Ln
k−
/−
 
an
d 
W
T 
m
ic
e
M
ic
ro
C
T
H
ist
ol
og
y
M
ic
e
n
BV
/T
V
 (%
)
SM
I
Tb
.
Th
 (m
m)
Tb
.
N
 (1
/m
m)
Tb
.
Sp
 (m
m)
n
BV
/T
V
 (%
)
N
.O
b/
 T
.
A
r
N
.O
c/
 T
.
A
r
BF
R
/T
V
 (μ
m3
/μ
m
2 /y
ea
r)
M
A
R
 (μ
m/
da
y)
C5
7B
L/
6 
(W
T)
38
3.
6 
± 
0.
3
2.
7 
± 
0.
1
0.
05
3 
± 
0.
00
2
0.
69
 ±
 0
.0
5
0.
34
 ±
 0
.0
1
12
3.
9 
± 
0.
8
59
 ±
 1
3
29
 ±
 4
34
6 
± 
33
1.
8 
± 
0.
1
Ln
k−
/−
18
7.
7 
± 
0.
7*
2.
4 
± 
0.
1*
0.
04
8 
± 
0.
00
2
1.
6 
± 
0.
1*
0.
25
 ±
 0
.0
1*
18
9.
8 
± 
1.
1*
52
 ±
 1
3
48
 ±
 4
*
26
4 
± 
16
*
1.
5 
± 
0.
1*
B
V
/T
V,
 
bo
ne
 v
o
lu
m
e/
tis
su
e 
vo
lu
m
e;
 S
M
I, 
str
uc
tu
re
 m
od
el
 in
de
x
; T
b.
Th
, t
ra
be
cu
la
r t
hi
ck
ne
ss
; T
b.
N
, t
ra
be
cu
la
r n
um
be
r; 
Tb
.
Sp
, t
ra
be
cu
la
r s
pa
ci
ng
; B
V
/T
V,
 
bo
ne
 v
o
lu
m
e/
tis
su
e 
vo
lu
m
e;
 N
.O
b/
T.
A
r, 
n
u
m
be
r 
o
f o
ste
ob
la
sts
/ti
ss
ue
 a
re
a;
 N
.O
c/
T.
A
r, 
n
u
m
be
r o
f o
ste
oc
la
sts
/ti
ss
ue
 a
re
a;
 B
FR
/T
V,
 
bo
ne
 fo
rm
at
io
n 
ra
te
/ti
ss
ue
 v
o
lu
m
e;
 M
A
R,
 m
in
er
al
 a
pp
os
iti
on
 ra
te
.
R
es
ul
ts 
ar
e 
pr
es
en
te
d 
as
 m
ea
n 
± 
SE
M
;
*
In
di
ca
te
s s
ig
ni
fic
an
t d
iff
er
en
ce
 c
om
pa
re
d 
to
 W
T 
(p<
0.0
5)
J Cell Biochem. Author manuscript; available in PMC 2018 August 01.
